| Title |
EGFR-TKI ADR Management Chinese Expert Consensus
|
|---|---|
| Published in |
Chinese Journal of Lung Cancer, February 2019
|
| DOI | 10.3779/j.issn.1009-3419.2019.02.01 |
| Pubmed ID | |
| Authors |
Chinese Anti-Cancer Association Chinese Society of Lung Cancer |
| Abstract |
ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China. And osimertinib was approved in second line setting for patients with EGFRT 790M-positive NSCLC. Rash, paronychia, diarrhea, stomatitis, liver dysfunction and (interstitial lung disease, ILD) are frequently observed in patients treated with EGFR-TKI. Chinese Society of Lung Cancer, Chinese Anti-Cancer Association, organized Chinese experts to develop the Chinese expert consensus on EGFR-TKI adverse event (AE) management based on domestic diagnosis and treatment of ADR and also incorporating international updated theory and recommendations. . |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 25% |
| Student > Ph. D. Student | 2 | 13% |
| Student > Doctoral Student | 1 | 6% |
| Student > Bachelor | 1 | 6% |
| Researcher | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 6 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Unknown | 7 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2022.
All research outputs
#3,417,018
of 25,385,509 outputs
Outputs from Chinese Journal of Lung Cancer
#5
of 381 outputs
Outputs of similar age
#73,777
of 366,923 outputs
Outputs of similar age from Chinese Journal of Lung Cancer
#1
of 5 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 381 research outputs from this source. They receive a mean Attention Score of 1.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 366,923 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them